Hutchison China MediTech, also known as Chi-Med, announced that it has filed for an initial public offering in the US. The company intends to list on NASDAQ under the symbol “HCM,” and has set a target of up to $100 million for the IPO, according to the filing. Bank of America Merrill Lynch and Deutsche Bank Securities are acting as joint bankers for the IPO. Established in 2000, Hutchison had revenue about $87.3 million in 2014, and currently has seven drug candidates in clinical-stage trials, three of which it is developing with AstraZeneca, Eli Lilly, and Nestlé Health Science.
Help employers find you! Check out all the jobs and post your resume.
